Associated tags: TPD, Therapy, Malignancy, Drug development, CTX, WSE, Cancer, Patient, Pharmaceutical industry, Hepatocellular carcinoma, Degenerative disease, HCC, Research, Medical imaging, IND, Vaccine
Locations: WROCLAW, PL, POLAND, LONDON, US
Partnership,
CTX,
WSE,
CSO,
Captor,
CT-05,
TPD,
Research,
Creativity,
PLN,
CFO,
Ono Pharmaceutical,
Therapy,
Environment,
Fine chemical,
Pharmaceutical industry WROCŁAW, Poland, May 30, 2023 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (“Captor”) (WSE: CTX), a biopharmaceutical company, specialized in the development of drugs based on Targeted Protein Degradation (TPD), today published its consolidated report for Q1 2023.
Key Points:
- WROCŁAW, Poland, May 30, 2023 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (“Captor”) (WSE: CTX), a biopharmaceutical company, specialized in the development of drugs based on Targeted Protein Degradation (TPD), today published its consolidated report for Q1 2023.
- In Q1 2023 Captor Therapeutics announced the next steps in the implementation of the Company’s 2023-25 strategy, aimed at becoming one of the global leaders in the TPD field.
- The Company also announced the new molecular targets its compounds are targeting and announced the latest research results from its lead projects CT-01, CT-02 and CT-05.
- This non-dilutive funding has been a key benefit to Captor since its inception, in particular considering the challenging financing environment the global Biotech industry has faced over the last 18 months," indicated Radosław Krawczyk, CFO at Captor Therapeutics.
Infection,
CTX,
Allergy,
Hepatocellular carcinoma,
WSE,
Glomus tumor,
Clinical trial,
Cancer,
NLRP3,
CT-05,
Breast,
TPD,
Research,
Lung,
Psoriasis,
Inflammatory bowel disease,
Malignancy,
Patient,
SALL4,
Liver,
GSPT1,
HCC,
Medical imaging,
Vaccine Dr Michal Walczak, Chief Scientific Officer and Co-founder of Captor, will present the scientific rational for these targets as well as the market potential of each of Captor’s lead programs and will answer questions during a webcast on March 30th 2023.
Key Points:
- Dr Michal Walczak, Chief Scientific Officer and Co-founder of Captor, will present the scientific rational for these targets as well as the market potential of each of Captor’s lead programs and will answer questions during a webcast on March 30th 2023.
- It is therefore expected that selective degradation of NEK7 would also remove the NEK7 scaffolding function leading to potent inflammatory inhibition.
- Pre-clinical studies have revealed the following benefits of CT-02:
CT-05 targets the PKCӨ protein, a protein highly relevant in both autoimmune diseases and cancer.
- It is therefore expected that degrading the PKCӨ protein would lead to an increased T cell suppressive function.
CT-05,
CTX,
Hepatocellular carcinoma,
Inflammation,
CT-03,
ADR,
Reward,
IPO,
Warsaw Stock Exchange,
TPD,
Carcinoma,
Biophysics,
CSO,
CFO,
Cancer,
E3,
Architecture,
Patient,
WSE,
Engineering,
Vaccine,
Pharmaceutical industry,
Medical imaging,
Biotechnology WROCŁAW, Poland, March 07, 2023 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (“Captor”) (WSE:CTX), a leader in the development of Targeted Protein Degradation (TPD)-based drugs, today announced its strategic objectives for the period 2023 to 2025 aimed at building a clinical stage, major international player in the rapidly growing TPD space.
Key Points:
- WROCŁAW, Poland, March 07, 2023 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (“Captor”) (WSE:CTX), a leader in the development of Targeted Protein Degradation (TPD)-based drugs, today announced its strategic objectives for the period 2023 to 2025 aimed at building a clinical stage, major international player in the rapidly growing TPD space.
- Dr. Tom Shepherd, CEO of Captor Therapeutics, said: “We have made great progress with taking our highly differentiated pipeline toward the clinic, keeping our TPD platform at the cutting edge of developments in the field, and signing a major strategic collaboration.
- Michał Walczak, CSO of Captor Therapeutics, said: “The field of Targeted Protein Degradation is advancing rapidly, with 18 degraders currently in clinical development to address life-threatening and life-impairing diseases.
- Radosław Krawczyk, CFO of Captor Therapeutics, said: “Accessing the global capital markets and, in particular, investors in the US, is an important aspect of our three-year strategic objectives.
Retrieved on:
Friday, November 25, 2022
TPD,
Degenerative disease,
Growth,
Liver cancer,
PLN,
CTX,
Monterrosa,
IND,
Ono Pharmaceutical,
R,
Partnership,
Biotechnology,
Therapy,
Patient,
IPO,
Ageing,
Parkinson's disease,
CNS,
CTA,
Neurodegeneration,
Cancer,
WSE,
Hepatocellular carcinoma,
Research,
Investigational New Drug,
GPCR,
Clinical trial,
Pharmaceutical industry,
Fine chemical WROCAW, Poland, Nov. 25, 2022 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (WSE:CTX), a biopharmaceutical company dedicated to the development of Targeted Protein Degradation (TPD)-based drugs for the treatment for cancer and autoimmune diseases, reports its financial results for the third quarter of 2022 and provides a business update.
Key Points:
- WROCAW, Poland, Nov. 25, 2022 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (WSE:CTX), a biopharmaceutical company dedicated to the development of Targeted Protein Degradation (TPD)-based drugs for the treatment for cancer and autoimmune diseases, reports its financial results for the third quarter of 2022 and provides a business update.
- CT-01 is Captors lead asset and is being developed as a treatment for hepatocellular carcinoma (a form of liver cancer).
- Earlier pre-clinical studies allowed Captor to select the best drug candidate to progress to the clinic.
- The development path of Captor Therapeutics definitely fits the sought-after growth model of a biotech company.
Retrieved on:
Monday, November 14, 2022
TPD,
WSE,
R,
Senior,
Neurodegeneration,
Therapy,
Discovery,
CTX,
Cancer,
Research,
Degenerative disease,
Ono Pharmaceutical,
Protein,
Drug discovery,
Neurology,
Patient,
Antibody,
Pharmaceutical industry Ono will be granted an exclusive option to license global rights to such candidates and will be responsible for further development and commercialization.
Key Points:
- Ono will be granted an exclusive option to license global rights to such candidates and will be responsible for further development and commercialization.
- We hope that this new collaboration will lead to the creation of innovative drugs for patients suffering from neurodegenerative diseases."
- Ono Pharmaceutical Co., Ltd., headquartered in Osaka, is an R&D-oriented pharmaceutical company committed to creating innovative medicines in specific areas.
- Captor Therapeutics is a drug discovery and development company applying targeted protein degradation (TPD) technology to discover and develop breakthrough drugs for diseases with significant unmet medical need.
Retrieved on:
Wednesday, August 10, 2022
CTX,
Hepatocellular carcinoma,
Eukaryote,
Cancer,
GLOBE,
CDMO,
TPD,
Technology,
Clinical trial,
IND,
SALL4,
GSPT1,
Patient,
Therapy,
Company,
HCC,
GTP,
WSE,
Contract,
Ligase,
Degenerative disease,
Entrepreneurship,
Pharmaceutical industry,
Vaccine The announcement of the drug candidate confirms that CPT-6281 is on track to enter the clinical phase in 2023.
Key Points:
- The announcement of the drug candidate confirms that CPT-6281 is on track to enter the clinical phase in 2023.
- Following the selection of the lead drug candidate, Captor has initiated large scale synthesis with a reputable Contract Development and Manufacturing Organization.
- In the CT-01 project, we are entering the advanced stage of preclinical development of the drug candidate, i.e.
- Captor is progressing according to plan and will deliver on its promises to enter the clinical phase in 2023.
University of Strasbourg,
Drug development,
AAP,
EDT,
University,
Laboratory,
Gastrointestinal disease,
GLOBE,
Liver disease,
CTX,
Cell,
Viral,
WSE,
Cancer,
Excellence,
ERC,
Cell Host & Microbe,
Doctor of Philosophy,
Funding of science,
Hepatocellular carcinoma,
Association,
American Association,
Degenerative disease,
Therapy,
Computational Biology Department,
Patent,
Virology,
PNAS,
Journal,
MD,
Research and development,
R,
Institute of Liver and Biliary Sciences,
CEST,
Center,
Infection,
HCC,
TPD,
European Research Council,
Editing,
American Association of Physician Specialists,
Technology,
Biology,
Chronic liver disease,
Pharmaceutical industry,
Hepatology,
Physician,
Gastroenterology,
Nature Furthermore, he is the founder of Alentis Therapeutics, a Swiss/French biotech company developing novel therapeutics for fibrotic diseases and cancer.
Key Points:
- Furthermore, he is the founder of Alentis Therapeutics, a Swiss/French biotech company developing novel therapeutics for fibrotic diseases and cancer.
- Captor Therapeutics is a biopharmaceutical company focused on leveraging Targeted Protein Degradation (TPD) technology to discover and develop breakthrough drug candidates in diseases with high unmet medical needs.
- Captor is currently developing therapeutics for undertreated severe conditions, including malignancies and autoimmune diseases.
- More information on Captor Therapeutics is available at: http://www.captortherapeutics.com
Disease,
Drug development,
Eukaryote,
Therapy,
Degenerative disease,
DNA,
GTP,
GSPT1,
CTX,
ORR,
IND,
Hepatocellular carcinoma,
Cancer,
WSE,
RNA,
Ribosome,
Neoplasm,
Technology,
Protein,
SALL4,
Liver cancer,
GLOBE,
HCC,
Project,
Patient,
TPD,
Medical imaging,
Pharmaceutical industry,
Bevacizumab "The CT-01 targets fundamentally contribute to cancer development and their elimination has potent therapeutic potential in the treatment hepatocellular carcinoma as well as several other malignances," said Dr Tom Shepherd, Chief Executive Officer of Captor Therapeutics.
Key Points:
- "The CT-01 targets fundamentally contribute to cancer development and their elimination has potent therapeutic potential in the treatment hepatocellular carcinoma as well as several other malignances," said Dr Tom Shepherd, Chief Executive Officer of Captor Therapeutics.
- Captor Therapeutics plans to advance CT-01 towards Investigational New Drug Application (IND)-enabling studies and to initiate clinical trials in 2023.
- Captor Therapeutics is a biopharmaceutical company focused on leveraging Targeted Protein Degradation (TPD) technology to discover and develop breakthrough drug candidates in diseases with high unmet medical needs.
- Captor is currently developing therapeutics for undertreated severe conditions, including malignancies and autoimmune diseases.
GLOBE,
Drug development,
Therapy,
Technology,
Degenerative disease,
Congress,
Cancer,
CTX,
TPD,
WSE,
Vaccine WROCLAW, Poland, April 11, 2022 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (WSE:CTX), a biopharmaceutical company focused on the development of targeted protein degradation (TPD) drugs for cancer and autoimmune diseases, today announces that it has been invited to participate in the 8 th Annual LSX World Congress , taking place in London from 10th to 11th May 2022.
Key Points:
- WROCLAW, Poland, April 11, 2022 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (WSE:CTX), a biopharmaceutical company focused on the development of targeted protein degradation (TPD) drugs for cancer and autoimmune diseases, today announces that it has been invited to participate in the 8 th Annual LSX World Congress , taking place in London from 10th to 11th May 2022.
- Dr. Tom Shepherd, Chief Executive Officer of Captor Therapeutics, will participate in an expert panel discussion focused on Targeted Protein Degradation and will also take part in partnering meetings.
- Details of the panel discussion:
To register for the event, click here
To request a one-on-one meeting with the Captor team, please contact us at [email protected] or at [email protected] .
- Captor Therapeutics is a biopharmaceutical company focused on leveraging Targeted Protein Degradation (TPD) technology to discover and develop breakthrough drug candidates in diseases with high unmet medical needs.
Retrieved on:
Thursday, January 13, 2022
Molecular glue,
Liver cancer,
Patient,
Technology,
CT-03,
Cancer,
Project,
CTX,
WSE,
Hepatocellular carcinoma,
Disease,
GLOBE,
ORR,
IND,
TPD,
Therapy,
Company,
Drug development,
Toxicity,
Neoplasm,
HCC,
Degenerative disease,
Medical imaging,
Bevacizumab Simultaneously, the data demonstrate the tolerability of both CT-01 candidates, as no treatment-related toxicity was observed.
Key Points:
- Simultaneously, the data demonstrate the tolerability of both CT-01 candidates, as no treatment-related toxicity was observed.
- "These preclinical data represent a significant milestone in the development of one of our core pipeline projects," said Dr Tom Shepherd, Chief Executive Officer of Captor Therapeutics.
- "Hepatocellular carcinoma is a very common cancer, but remains difficult to treat with few effective therapies and poor prognosis for most patients.
- CT-01 is Captor Therapeutics' second pipeline project to produce in vivo data recently, following positive pharmacological results from the CT-03 project.
